Universal Health Realty Income

Valuation Analysis

About the Company

Universal Health Realty Income en bref

Universal Health Realty Income (UHT) is currently trading at 33,00 € with a market capitalization of 458 M €. The trailing P/E ratio stands at 29.58x. The 52-week range spans from 30,74 € to 38,97 €; the current price is 15.3% below the yearly high. Year-over-year revenue growth stands at +0.3%. The net profit margin stands at 17.68%.

💰 Dividende

Universal Health Realty Income pays an annual dividend of 2,62 € per share, representing a yield of 7.92%. The payout ratio stands at 232.03%. The elevated payout ratio reflects a mature dividend policy.

📊 Avis des analystes

1 analystes évaluent Universal Health Realty Income (UHT) au consensus : None. L'objectif de cours moyen est de 36,61 €, soit un potentiel de +10.94% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 36,61 € à 36,61 €.

Universal Health Realty Income : la thèse d'investissement en détail

Universal Health Realty Income (UHT) operates in the Real Estate — specifically REIT - Healthcare Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

With a gross margin near 94.42%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 17.68%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Revenue growth has slowed to just 0.3%, which is below nominal GDP — the business is no longer outgrowing the broader economy. The debt-to-equity ratio of 263.32% is elevated, meaning the company relies heavily on creditors — refinancing terms will become more important than operational performance in the next economic downturn.

Valorisation en contexte

With a PEG ratio of 0.63, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, higher leverage relative to equity.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Universal Health Realty Income ?

Compare top-rated brokers — low fees, trusted providers, fully regulated.